Valeant Tells Regulators Allergan Is Misleading Investors

Law360, New York (July 21, 2014, 4:04 PM ET) -- Valeant Pharmaceuticals International Inc. said Monday it has contacted U.S. and Canadian regulators saying Allergan Inc., the Botox maker and target of it and activist investor Bill Ackman's $53 billion takeover, was trying to mislead investors over the performance of Valeant’s Bausch & Lomb Inc. business.

The pharmaceutical company, which purchased Bausch & Lomb almost a year ago, said it has contacted both the U.S. Securities and Exchange Commission and the Autorite des marches in Quebec over statements Allergen made in a regulatory filing last week...
To view the full article, register now.